We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

CETA and Canadian IP law: Possible changes ahead?
  • Gowling WLG
  • Canada, European Union
  • March 3 2016

In 2013, an agreement in principle was reached between Canada and the European Union - theCanada-European Union Comprehensive Economic and Trade


Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)
  • Gowling WLG
  • Canada
  • October 27 2010

This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998


Eli Lilly Canada inc. v. Apotex Inc. (2010 FC 952)
  • Gowling WLG
  • Canada
  • October 27 2010

Apotex brought a motion to set aside an Order from 2007 granting Eli Lilly’s applications for a prohibition Order in PMNOC proceedings


Epicept Corporation v. Canada (Health) (2010 FC 956)
  • Gowling WLG
  • Canada
  • October 27 2010

The Minister of Health refused to grant data exclusivity to data from Epicept’s phase I and phase II clinical trials because CEPLENE is not an “innovative drug”


Sanofi v ratiopharm, PMNOC Regulations decision irbesartan, March 5, 2010
  • Gowling WLG
  • Canada
  • May 21 2010

Sanofi sought an order prohibiting the granting of a NOC to ratiopharm


Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling WLG
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe


Time for change? Potential impact of Canada’s trade negotiations on pharma patents
  • Gowling WLG
  • Canada
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this


Novopharm v Pfizer, motion for interim relief pending appeal, pregabalin, October 5, 2010
  • Gowling WLG
  • Canada
  • November 24 2010

See the earlier decisions in this case in the May 2010 and July 2010 editions of this newsletter


Merck v Apotex, PMNOC proceedings, dorzolamide and timolol, October 22, 2010
  • Gowling WLG
  • Canada
  • November 24 2010

Merck’s patent in this case (the ‘965 patent) covered the co-administration and co-formulation of dorzolamide and timolol (which was sold as COSOPT


Hospira v Eli Lilly, appeal of order for further and better production of documents, gemcitabine, October 26, 2010
  • Gowling WLG
  • Canada
  • November 24 2010

Eli Lilly alleged that gemcitabine made in China and imported into Canada by Hospira infringes Eli Lilly's patent for an intermediate process step in the manufacture of gemcitabine